| 摘要 |
Compounds of formula (I) or a pharmaceutically acceptable salt thereof: <IMAGE> (I) wherein: j is 0 or 1; q is 0, 1 or 2; p is 0 and r is 2 or 3, or p is 1 and r is 2; X is O, S, SO or NR where R is hydrogen, C1-6 alkyl or C1-10 carboxylic acyl; Y is NH; or O when R1 is hydrogen; either R1 is C1-6 alkoxy and one of R2, R3 and R4 is hydrogen and the other two are selected from hydrogen, halogen, CF3, C1-6 alkylthio, C1-7 acyl, C1-10 carboxylic acylamino, C1-6 alkyl S(O) n wherein n is 0, 1 or 2, nitro or amino, aminocarbonyl or aminosulphonyl optionally substituted by one or two groups selected from C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl C1-4 alkyl or phenyl C1-4 alkyl groups any of which phenyl moieties may be substituted by one or two groups selected from halogen, CF3, C1-6 alkyl or C1-6 alkoxy; or R1 is hydrogen and R2, R3 and R4 are independently selected from hydrogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio or halo; or any two on adjacent carbon atoms together are C1-2 alkylenedioxy and the third is hydrogen, C1-6 alkyl, C 1-6 alkoxy or halo; one of R5 and R6 is hydrogen, C1-6 alkyl, phenyl or phenyl-C1-6 alkyl, which phenyl moieties may be substituted by C1-6 alkyl, C1-6 alkoxy or halogen; and the other is hydrogen or C1-6 alkyl; and R7 is hydrogen, C1-6 alkyl, phenyl or phenyl-C1-3 alkyl, which phenyl moieties may be substituted by C1-6 alkyl, C1-6 alkoxy, CF3 or halogen having gastric motility enhancing activity, anti-emetic activity and/or 5-HT receptor antagonist activity, a process and intermediates for their preparation and their use as pharmaceuticals.
|
